Oncology

With a new grant, Tessera Therapeutics is advancing its novel Gene Writing platform to engineer a scalable, single-shot cure for HIV. But can it work?

Genomics leader IDT launches its first IVD-grade NGS tests for cancer, aiming to standardize diagnostics and accelerate precision medicine.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

A top university and a global clinical research firm unite to slash drug development timelines, aiming to bring innovative therapies to patients faster.

With six top honors at a key summit, Fortis Healthcare highlights India's rapid growth as a trusted, affordable destination for advanced medical treatment.

The pharma giant is acquiring a promising 'best-in-class' PI3Kα inhibitor, SNV4818, in a move to bolster its oncology pipeline and redefine cancer care.

A novel drug designed to eliminate stubborn cancer proteins enters human trials, offering a new strategy for ALK+ lung cancer patients facing resistance.

A landmark study reveals GLP-1 drugs like Ozempic dramatically reduce risks of depression and anxiety, hinting at a new era for mental healthcare.

After his own diagnosis, golfer Brian Gay advocates for GentleCure, a non-surgical option with a 99% cure rate that kept him on the course.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

DNA Script's global expansion brings benchtop DNA printers to new markets, promising to accelerate research and decentralize biotech supply chains.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

A new biotech firm unveils a first-in-class cancer drug targeting E6AP, aiming to restore the body's natural defenses against HPV-positive head and neck cancer.

Pharma giant AbbVie taps biotech innovator Alloy Therapeutics to build a novel antibody platform, aiming to unlock a new generation of medicines.

With promising clinical data for its lead drug silevertinib and a strong new financial position, Black Diamond Therapeutics charts a dual course for two deadly cancers.

JAMP Pharma Group introduces a generic version of a key prostate cancer drug, aiming to reduce healthcare costs and enhance patient support in Canada.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

As it advances its brain cancer therapies, NeOnc Technologies hires a public company finance expert to steer its next growth phase and ensure fiscal rigor.

Aditxt's $36M acquisition of Ignite Proteomics aims to upend cancer therapy by analyzing protein activity, a high-stakes bet for the struggling innovator.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.